Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) will report first quarter 2026 financial results on Wednesday, May 6, 2026 with a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. A recorded version will be posted to the company's website shortly after the call and archived for approximately 90 days.

News Market Reaction – TARS

+4.85%

+4.85% Session close to close

In the Apr 30 session, TARS gained 4.85%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the schedule for Tarsus’s Q1 2026 earnings webcast on May 6, 2026, continuing...

Analysis

This announcement sets the schedule for Tarsus’s Q1 2026 earnings webcast on May 6, 2026, continuing a consistent pattern of providing timing and replay access for about 90 days. In recent months, the company reported robust 2025 sales for XDEMVY and advanced multiple clinical programs. Investors may watch how upcoming results update that trajectory, especially given shares trade below the 200-day MA of $65.79 and well under the 52-week high.

Key Figures

Webcast time (PT): 1:30 p.m. PT Webcast time (ET): 4:30 p.m. ET Replay duration: 90 days

3 metrics

Webcast time (PT) 1:30 p.m. PT Scheduled Q1 2026 results webcast on May 6, 2026

Webcast time (ET) 4:30 p.m. ET Scheduled Q1 2026 results webcast on May 6, 2026

Replay duration 90 days Recorded webcast archived on company website

Previous Earnings date Reports

1 past event · Latest: Feb 17 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Earnings date notice	Neutral	+0.8%	Announced timing and webcast details for Q4 and full-year 2025 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past earnings-date scheduling news led to a modest +0.78% move, suggesting limited but positive pre-announcement repricing.

Recent Company History

Recent Tarsus news featured earnings, clinical progress, and strategic updates. A prior earnings date announcement on Feb 17, 2026 preceded a mild +0.78% move, indicating modest anticipation around scheduled results. Subsequent full-year 2025 earnings delivery saw stronger appreciation, while clinical and partnership milestones drove mixed but generally constructive reactions. Today’s announcement of the Q1 2026 results date continues this pattern of structured communication and webcast access for investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus (TARS) report Q1 2026 results and how can I listen?

Tarsus will report Q1 2026 results on May 6, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. According to Tarsus, the event will be available via a live webcast on the company's investor website, with a recording posted afterward and archived for about 90 days.

Will Tarsus (TARS) provide a recorded replay of the May 6, 2026 webcast?

Yes. According to Tarsus, a recorded version will be available shortly after the webcast and will be archived on the company's website for approximately 90 days for later viewing by investors and analysts.

What time is the Tarsus (TARS) investor webcast for Q1 2026 in Eastern Time?

The webcast is scheduled for 4:30 p.m. ET on May 6, 2026. According to Tarsus, the live event begins at 1:30 p.m. PT / 4:30 p.m. ET and will include the company's financial results and a corporate update.

Where can investors find materials or the link for the Tarsus (TARS) May 6, 2026 webcast?

Investors can access the webcast link on the company's investor relations website. According to Tarsus, participants may join the live webcast there and the recording will be posted and archived on the same site for about 90 days.

What should shareholders expect from the Tarsus (TARS) May 6, 2026 corporate update?

Shareholders should expect a first quarter 2026 financial results presentation plus a corporate update during the webcast. According to Tarsus, management will present results and company developments, with the replay available afterward for those who cannot attend live.